v3.26.1
Segment Reporting - Significant expenses (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting            
Revenue $ 357,693       $ 601,964 $ 14,720
Less:            
Cost of revenue           (48)
Gross Profit 357,693       601,964 14,672
Research and Development:            
Salaries and benefits 44,120   $ 424,032   167,226 844,032
Direct clinical and non-clinical expenses 6,707   16,263   67,548 88,920
Facilities expenses 1,256   62,432   13,044 133,269
Non-cash stock based compensation expenses 4,187   157,291   43,121 221,968
Supplies and materials           25,130
Other expenses 2,221   14,560   6,101 34,302
Depreciation expense         (48,215)  
Realized gain - digital assets and digital assets receivable (17,859,505)       (21,483,269)  
Unrealized gain - digital assets (16,939,634)       (27,913,613)  
Unrealized loss - digital intangible assets receivable 367,251          
Impairment loss - digital intangible assets 768,857       2,000,525  
Net gain on derivative instruments (112,032)       (151,433)  
Recovery of credit losses (909,842)       (405,331)  
Segment (income) loss (34,984,107)   674,578   (48,209,830) 1,347,621
Selling, general and administrative expense 3,918,592   7,678,704   8,412,196 10,051,026
Impairment of right of use assets 57,773       57,773  
Other expense, net 56,779   337,637   (51,652) 790,477
Net Income (Loss) 30,950,963 $ 8,840,550 (8,690,919) $ (3,483,533) 39,791,513 (12,174,452)
Operating Segments | Ophthalmic Technology            
Segment Reporting            
Revenue           14,720
Less:            
Cost of revenue           (48)
Gross Profit           14,672
Research and Development:            
Salaries and benefits     424,032     844,032
Direct clinical and non-clinical expenses     16,263     88,920
Facilities expenses     62,432     133,269
Non-cash stock based compensation expenses     157,291     221,968
Supplies and materials           25,130
Other expenses     14,560     34,302
Segment (income) loss     674,578     1,347,621
Net Income (Loss)     (674,578)     (1,332,949)
Operating Segments | Digital Assets            
Segment Reporting            
Revenue 357,693       601,964  
Less:            
Gross Profit 357,693       601,964  
Research and Development:            
Realized gain - digital assets and digital assets receivable (17,859,505)       (21,483,269)  
Unrealized gain - digital assets (16,939,634)       (27,913,613)  
Unrealized loss - digital intangible assets receivable 367,251          
Impairment loss - digital intangible assets 768,857       2,000,525  
Net gain on derivative instruments (112,032)       (151,433)  
Recovery of credit losses (909,842)       (405,331)  
Segment (income) loss (35,042,598)       (48,555,085)  
Net Income (Loss) 35,042,598       48,555,085  
Corporate / Other            
Research and Development:            
Salaries and benefits 44,120       167,226  
Direct clinical and non-clinical expenses 6,707       67,548  
Facilities expenses 1,256       13,044  
Non-cash stock based compensation expenses 4,187       43,121  
Other expenses 2,221       6,101  
Depreciation expense         (48,215)  
Segment (income) loss 58,491       345,255  
Selling, general and administrative expense 3,918,592   7,678,704   8,412,196 10,051,026
Impairment of right of use assets 57,773       57,773  
Other expense, net 56,779   337,637   (51,652) 790,477
Net Income (Loss) $ (4,091,635)   $ (8,016,341)   $ (8,763,572) $ (10,841,503)